Regeneron Pharmaceuticals (NASDAQ:REGN) Price Target Raised to $800.00

Regeneron Pharmaceuticals (NASDAQ:REGN) had its target price raised by stock analysts at Wells Fargo & Company from $745.00 to $800.00 in a report issued on Monday,Benzinga reports. The brokerage currently has an “equal weight” rating on the biopharmaceutical company’s stock. Wells Fargo & Company‘s target price indicates a potential upside of 5.08% from the stock’s current price.

A number of other analysts have also recently commented on the company. Canaccord Genuity Group boosted their price objective on Regeneron Pharmaceuticals from $850.00 to $1,057.00 and gave the company a “buy” rating in a research report on Thursday, December 4th. Wall Street Zen cut shares of Regeneron Pharmaceuticals from a “buy” rating to a “hold” rating in a research note on Saturday. Scotiabank upped their price objective on shares of Regeneron Pharmaceuticals from $650.00 to $770.00 and gave the stock a “sector perform” rating in a research report on Monday, November 24th. Truist Financial decreased their price objective on shares of Regeneron Pharmaceuticals from $820.00 to $818.00 and set a “buy” rating on the stock in a report on Monday. Finally, Citigroup boosted their target price on shares of Regeneron Pharmaceuticals from $660.00 to $700.00 and gave the stock a “buy” rating in a research note on Wednesday, October 29th. Three research analysts have rated the stock with a Strong Buy rating, sixteen have assigned a Buy rating and eight have issued a Hold rating to the company’s stock. According to data from MarketBeat.com, the stock has an average rating of “Moderate Buy” and a consensus price target of $789.91.

Regeneron Pharmaceuticals Price Performance

Shares of Regeneron Pharmaceuticals stock traded up $19.87 during trading hours on Monday, reaching $761.32. The stock had a trading volume of 139,659 shares, compared to its average volume of 884,757. The stock’s 50 day moving average is $758.39 and its 200 day moving average is $651.29. The company has a current ratio of 4.77, a quick ratio of 4.22 and a debt-to-equity ratio of 0.09. Regeneron Pharmaceuticals has a twelve month low of $476.49 and a twelve month high of $821.11. The firm has a market capitalization of $80.01 billion, a PE ratio of 18.32, a PEG ratio of 1.92 and a beta of 0.40.

Regeneron Pharmaceuticals (NASDAQ:REGN) last posted its earnings results on Friday, January 30th. The biopharmaceutical company reported $11.44 EPS for the quarter, beating analysts’ consensus estimates of $10.74 by $0.70. The firm had revenue of $3.88 billion for the quarter, compared to analysts’ expectations of $3.76 billion. Regeneron Pharmaceuticals had a return on equity of 13.04% and a net margin of 31.41%.The company’s quarterly revenue was up 2.5% on a year-over-year basis. During the same period last year, the firm earned $12.07 EPS. Equities analysts expect that Regeneron Pharmaceuticals will post 35.92 earnings per share for the current fiscal year.

Insider Transactions at Regeneron Pharmaceuticals

In related news, Director Bonnie L. Bassler sold 1,500 shares of the company’s stock in a transaction dated Wednesday, January 7th. The shares were sold at an average price of $800.00, for a total transaction of $1,200,000.00. Following the completion of the sale, the director owned 1,703 shares of the company’s stock, valued at approximately $1,362,400. This represents a 46.83% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, VP Jason Pitofsky sold 431 shares of the firm’s stock in a transaction that occurred on Friday, November 7th. The stock was sold at an average price of $651.43, for a total transaction of $280,766.33. Following the completion of the transaction, the vice president directly owned 4,233 shares in the company, valued at $2,757,503.19. This trade represents a 9.24% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Insiders own 7.02% of the company’s stock.

Institutional Trading of Regeneron Pharmaceuticals

Several large investors have recently added to or reduced their stakes in the stock. WPG Advisers LLC boosted its position in shares of Regeneron Pharmaceuticals by 312.5% during the 4th quarter. WPG Advisers LLC now owns 33 shares of the biopharmaceutical company’s stock valued at $25,000 after acquiring an additional 25 shares during the last quarter. Salomon & Ludwin LLC purchased a new position in Regeneron Pharmaceuticals during the third quarter worth about $27,000. Migdal Insurance & Financial Holdings Ltd. purchased a new position in Regeneron Pharmaceuticals during the second quarter worth about $31,000. Board of the Pension Protection Fund acquired a new position in Regeneron Pharmaceuticals in the 4th quarter valued at about $31,000. Finally, Caitlin John LLC purchased a new stake in shares of Regeneron Pharmaceuticals in the 3rd quarter valued at approximately $34,000. 83.31% of the stock is currently owned by hedge funds and other institutional investors.

Regeneron Pharmaceuticals Company Profile

Regeneron Pharmaceuticals, Inc (NASDAQ: REGN) is a U.S.-based biotechnology company founded in 1988 and headquartered in Tarrytown, New York. It focuses on discovering, developing, manufacturing and commercializing medicines for serious medical conditions. The company combines laboratory research, clinical development and in-house manufacturing to advance a pipeline of biologic therapies across multiple therapeutic areas.

Regeneron is known for its proprietary drug discovery technologies, including its VelocImmune platform, which is used to generate fully human monoclonal antibodies.